The Impact of 5-HT(3)RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature

Lignende værker

• Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
  af: Powers, Annette, et al.
  Udgivet: (2012)
• Outcomes Associated with 5-HT(3)-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis
  af: Faria, Claudio, et al.
  Udgivet: (2014)
• 5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
  af: Hayashi, Toshinobu, et al.
  Udgivet: (2020)
• An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries
  af: Turini, Marco, et al.
  Udgivet: (2015)
• Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
  af: Restelli, Umberto, et al.
  Udgivet: (2017)